{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:51:30Z","timestamp":1781311890877,"version":"3.54.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T00:00:00Z","timestamp":1716249600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005888","name":"Medical University of Lodz","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005888","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Medical Sciences"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.advms.2024.05.001","type":"journal-article","created":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T07:01:04Z","timestamp":1716274864000},"page":"256-263","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Cefiderocol \u2013 An effective antimicrobial for MDR infections but a challenge for routine antimicrobial susceptibility testing"],"prefix":"10.1016","volume":"69","author":[{"given":"Ma\u0142gorzata","family":"Brauncajs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4446-0802","authenticated-orcid":false,"given":"Filip","family":"Bielec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Macieja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorota","family":"Pastuszak-Lewandoska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.advms.2024.05.001_bib1","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.00951-20","article-title":"Cefiderocol antimicrobial susceptibility testing considerations: the achilles' heel of the trojan horse?","volume":"59","author":"Simner","year":"2020","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.advms.2024.05.001_bib2","doi-asserted-by":"crossref","first-page":"S538","DOI":"10.1093\/cid\/ciz826","article-title":"Cefiderocol: discovery, chemistry, and in vivo profiles of a novel siderophore cephalosporin","volume":"69","author":"Sato","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.advms.2024.05.001_bib3","year":"2022","journal-title":"Fetcroja"},{"key":"10.1016\/j.advms.2024.05.001_bib4","series-title":"M100: performance standards for antimicrobial susceptibility testing","year":"2024"},{"key":"10.1016\/j.advms.2024.05.001_bib7","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s40265-019-1055-2","article-title":"Cefiderocol: a siderophore cephalosporin with activity against carbapenem-resistant and multidrug-resistant gram-negative bacilli","volume":"79","author":"Zhanel","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.advms.2024.05.001_bib8","doi-asserted-by":"crossref","first-page":"S529","DOI":"10.1093\/cid\/ciz825","article-title":"The role of iron and siderophores in infection, and the development of siderophore antibiotics","volume":"69","author":"Page","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.advms.2024.05.001_bib9","doi-asserted-by":"crossref","first-page":"S544","DOI":"10.1093\/cid\/ciz827","article-title":"In vitro activity of cefiderocol against a broad range of clinically important gram-negative bacteria","volume":"69","author":"Yamano","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.advms.2024.05.001_bib10","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.3390\/pathogens11121508","article-title":"Cefiderocol against multi-drug and extensively drug-resistant Escherichia coli: an in vitro study in Poland","volume":"11","author":"Zalas-Wi\u0119cek","year":"2022","journal-title":"Pathogens"},{"issue":"3","key":"10.1016\/j.advms.2024.05.001_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0123690","article-title":"The carbapenem inactivation method (CIM), a simple and low-cost alternative for the Carba NP test to assess phenotypic carbapenemase activity in gram-negative rods","volume":"10","author":"van der Zwaluw","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.advms.2024.05.001_bib15","series-title":"Krajowy O\u015brodek Referencyjny ds. Lekowra\u017cliwo\u015bci Drobnoustroj\u00f3w. Wykrywanie karbapenemaz\u2013zalecenia KORLD","year":"2017"},{"key":"10.1016\/j.advms.2024.05.001_bib16","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s40121-020-00286-6","article-title":"Cefiderocol: a novel agent for the management of multidrug-resistant gram-negative organisms","volume":"9","author":"Wu","year":"2020","journal-title":"Infect Dis Ther"},{"issue":"4","key":"10.1016\/j.advms.2024.05.001_bib17","doi-asserted-by":"crossref","first-page":"230","DOI":"10.2533\/chimia.2023.230","article-title":"Clinically approved antibiotics from 2010 to 2022","volume":"77","author":"Jung","year":"2023","journal-title":"Chimia"},{"key":"10.1016\/j.advms.2024.05.001_bib18","article-title":"Meropenem-vaborbactam as salvage therapy for ceftazidime-avibactam-resistant Klebsiella pneumoniae bacteremia and abscess in a liver transplant recipient","volume":"63","author":"Athans","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.advms.2024.05.001_bib19","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.01649-20","article-title":"Cefiderocol antimicrobial susceptibility testing against multidrug-resistant gram-negative bacilli: a comparison of disk diffusion to broth microdilution","volume":"59","author":"Morris","year":"2020","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.advms.2024.05.001_bib20","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1093\/jac\/dkac080","article-title":"Cefiderocol: EUCAST criteria for disc diffusion and broth microdilution for antimicrobial susceptibility testing","volume":"77","author":"Matuschek","year":"2022","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.advms.2024.05.001_bib21","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ijantimicag.2018.11.007","article-title":"In vitro activity of cefiderocol, a siderophore cephalosporin, against gram-negative bacilli isolated by clinical laboratories in north America and europe in 2015-2016: sidero-WT-2015","volume":"53","author":"Karlowsky","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.advms.2024.05.001_bib23","volume":"vol. 3","author":"Naas","year":"2021"},{"key":"10.1016\/j.advms.2024.05.001_bib24","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jgar.2021.04.019","article-title":"In vitro activity of cefiderocol and comparators against isolates of Gram-negative pathogens from a range of infection sources: SIDERO-WT-2014-2018 studies in Italy","volume":"25","author":"Stracquadanio","year":"2021","journal-title":"J\u00a0Glob Antimicrob Resist"},{"issue":"3","key":"10.1016\/j.advms.2024.05.001_bib25","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s10096-024-04745-7","volume":"43","author":"Bianco","year":"2024","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"3","key":"10.1016\/j.advms.2024.05.001_bib26","doi-asserted-by":"crossref","first-page":"604","DOI":"10.3390\/antibiotics12030604","article-title":"Disc diffusion and ComASP\u00ae cefiderocol microdilution panel to overcome the challenge of cefiderocol susceptibility testing in clinical laboratory routine","volume":"12","author":"Bianco","year":"2023","journal-title":"Antibiotics (Basel)"},{"issue":"3","key":"10.1016\/j.advms.2024.05.001_bib27","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02670-21","article-title":"Occurrence of high levels of cefiderocol resistance in carbapenem-resistant Escherichia coli before its approval in China: a report from China CRE-network","volume":"10","author":"Wang","year":"2022","journal-title":"Microbiol Spectr"},{"issue":"2","key":"10.1016\/j.advms.2024.05.001_bib28","doi-asserted-by":"crossref","DOI":"10.1128\/aac.02011-21","article-title":"New Delhi metallo-beta-lactamase facilitates the emergence of cefiderocol resistance in Enterobacter cloacae","volume":"66","author":"Nurjadi","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1016\/j.advms.2024.05.001_bib29","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1080\/23744235.2023.2226709","article-title":"Higher rates of cefiderocol resistance among NDM producing Klebsiella bloodstream isolates applying EUCAST over CLSI breakpoints","volume":"55","author":"Isler","year":"2023","journal-title":"Inf Disp"},{"issue":"Suppl 1","key":"10.1016\/j.advms.2024.05.001_bib30","doi-asserted-by":"crossref","first-page":"S251","DOI":"10.1093\/ofid\/ofy210.703","article-title":"696. Mechanism of Cefiderocol high MIC mutants obtained in non-clinical FoR studies","volume":"5","author":"Ito","year":"2018","journal-title":"Open Forum Infect Dis"},{"issue":"8","key":"10.1016\/j.advms.2024.05.001_bib31","doi-asserted-by":"crossref","first-page":"1156.e1","DOI":"10.1016\/j.cmi.2022.04.013","article-title":"Comparison of disk diffusion, MIC test strip and broth microdilution methods for cefiderocol susceptibility testing on carbapenem-resistant enterobacterales","volume":"28","author":"Bonnin","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.advms.2024.05.001_bib32","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00198-20","article-title":"Structural basis of reduced susceptibility to ceftazidime-avibactam and cefiderocol in Enterobacter cloacae due to AmpC R2 loop deletion","volume":"64","author":"Kawai","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.advms.2024.05.001_bib35","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.3390\/microorganisms11081971","article-title":"Performance of the disc diffusion method, MTS gradient tests and two commercially available microdilution tests for the determination of cefiderocol susceptibility in acinetobacter spp","volume":"11","author":"Jeannot","year":"2023","journal-title":"Microorganisms"}],"container-title":["Advances in Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1896112624000300?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1896112624000300?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T17:00:38Z","timestamp":1730739638000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1896112624000300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S1896112624000300"],"URL":"https:\/\/doi.org\/10.1016\/j.advms.2024.05.001","relation":{},"ISSN":["1896-1126"],"issn-type":[{"value":"1896-1126","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cefiderocol \u2013 An effective antimicrobial for MDR infections but a challenge for routine antimicrobial susceptibility testing","name":"articletitle","label":"Article Title"},{"value":"Advances in Medical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.advms.2024.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V. on behalf of Medical University of Bialystok.","name":"copyright","label":"Copyright"}]}}